Anastasios G. Konidaris's Insider Trades & SAST Disclosures
Anastasios G. Konidaris's most recent trade in Amneal Pharmaceuticals Inc - Ordinary Shares - Class A was a trade of 100,000 Class A Common Stock done at an average price of $8.9 . Disclosure was reported to the exchange on March 5, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Anastasios G. Konidaris.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Amneal Pharmaceuticals Inc... | Anastasios G. Konidaris | Executive Vice President & CFO | Sale of securities on an exchange or to another person at price $ 8.91 per share. | 05 Mar 2025 | 100,000 | 621,882 (0%) | 0% | 8.9 | 891,000 | Class A Common Stock |
| Amneal Pharmaceuticals Inc... | Anastasios G. Konidaris | Executive Vice President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 228,310 | 228,310 | - | - | Performance-Based Restricted Stock Units | |
| Amneal Pharmaceuticals Inc... | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 181,159 | 0 | - | - | Performance-Based Restricted Stock Units | |
| Amneal Pharmaceuticals Inc... | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 181,159 | 793,061 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharmaceuticals Inc... | Anastasios G. Konidaris | Executive Vice President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 114,155 | 114,154 | - | - | Restricted Stock Units | |
| Amneal Pharmaceuticals Inc... | Anastasios G. Konidaris | Executive Vice President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.76 per share. | 03 Mar 2025 | 92,663 | 700,398 (0%) | 0% | 8.8 | 811,728 | Class A Common Stock |
| Amneal Pharmaceuticals Inc... | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 57,340 | 114,679 | - | - | Restricted Stock Units | |
| Amneal Pharmaceuticals Inc... | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 57,340 | 636,276 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharmaceuticals Inc... | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 45,290 | 45,290 | - | - | Restricted Stock Units | |
| Amneal Pharmaceuticals Inc... | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 45,290 | 595,309 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharmaceuticals Inc... | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 43,981 | 744,379 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharmaceuticals Inc... | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 43,981 | 131,945 | - | - | Restricted Stock Units | |
| Amneal Pharmaceuticals Inc... | Anastasios G. Konidaris | Executive Vice President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.76 per share. | 03 Mar 2025 | 24,374 | 611,902 (0%) | 0% | 8.8 | 213,516 | Class A Common Stock |
| Amneal Pharmaceuticals Inc... | Anastasios G. Konidaris | Executive Vice President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.84 per share. | 03 Mar 2025 | 22,497 | 721,882 (0%) | 0% | 8.8 | 198,873 | Class A Common Stock |
| Amneal Pharmaceuticals Inc... | Anastasios G. Konidaris | Executive Vice President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.76 per share. | 03 Mar 2025 | 16,373 | 578,936 (0%) | 0% | 8.8 | 143,427 | Class A Common Stock |
| Amneal Pharmaceuticals Inc... | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 36,197 | 563,513 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharmaceuticals Inc... | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 36,197 | 0 | - | - | Restricted Stock Units | |
| Amneal Pharmaceuticals Inc... | Anastasios G. Konidaris | Executive Vice President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.67 per share. | 01 Mar 2025 | 13,494 | 550,019 (0%) | 0% | 8.7 | 116,993 | Class A Common Stock |
| Amneal Pharmaceuticals Inc... | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2024 | 87,720 | 0 | - | - | Restricted Stock Units | |
| Amneal Pharmaceuticals Inc... | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2024 | 87,720 | 558,106 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharmaceuticals Inc... | Anastasios G. Konidaris | Executive Vice President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.31 per share. | 12 Mar 2024 | 30,790 | 527,316 (0%) | 0% | 5.3 | 163,495 | Class A Common Stock |
| Amneal Pharmaceuticals Inc... | Anastasios G. Konidaris | Executive Vice President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 351,852 | 351,852 | - | - | Performance-Based Restricted Stock Units | |
| Amneal Pharmaceuticals Inc... | Anastasios G. Konidaris | Executive Vice President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 175,926 | 175,926 | - | - | Restricted Stock Units | |
| Amneal Pharmaceuticals Inc... | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 57,339 | 172,019 | - | - | Restricted Stock Units | |
| Amneal Pharmaceuticals Inc... | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 57,339 | 490,512 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharmaceuticals Inc... | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 45,290 | 449,070 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharmaceuticals Inc... | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 45,290 | 90,580 | - | - | Restricted Stock Units | |
| Amneal Pharmaceuticals Inc... | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 36,197 | 417,037 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharmaceuticals Inc... | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 36,197 | 36,197 | - | - | Restricted Stock Units | |
| Amneal Pharmaceuticals Inc... | Anastasios G. Konidaris | Executive Vice President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.47 per share. | 01 Mar 2024 | 20,126 | 470,386 (0%) | 0% | 5.5 | 110,089 | Class A Common Stock |
| Amneal Pharmaceuticals Inc... | Anastasios G. Konidaris | Executive Vice President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.47 per share. | 01 Mar 2024 | 15,897 | 433,173 (0%) | 0% | 5.5 | 86,957 | Class A Common Stock |
| Amneal Pharmaceuticals Inc... | Anastasios G. Konidaris | Executive Vice President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.47 per share. | 01 Mar 2024 | 13,257 | 403,780 (0%) | 0% | 5.5 | 72,516 | Class A Common Stock |
| Amneal Pharmaceuticals Inc... | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2023 | 87,719 | 87,720 | - | - | Restricted Stock Units | |
| Amneal Pharmaceuticals Inc... | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2023 | 87,719 | 380,840 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharmaceuticals Inc... | Anastasios G. Konidaris | Executive Vice President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2023 | 458,716 | 458,716 | - | - | Performance-Based Restricted Stock Units | |
| Amneal Pharmaceuticals Inc... | Anastasios G. Konidaris | Executive Vice President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2023 | 229,358 | 229,358 | - | - | Restricted Stock Units | |
| Amneal Pharmaceuticals Inc... | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2023 | 45,289 | 135,870 | - | - | Restricted Stock Units | |
| Amneal Pharmaceuticals Inc... | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2023 | 45,289 | 293,121 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharmaceuticals Inc... | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 36,197 | 72,394 | - | - | Restricted Stock Units | |
| Amneal Pharmaceuticals Inc... | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 36,197 | 247,832 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharmaceuticals Inc... | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2022 | 87,719 | 211,635 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharmaceuticals Inc... | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2022 | 87,719 | 175,439 | - | - | Restricted Stock Units | |
| Amneal Pharmaceuticals Inc... | Anastasios G. Konidaris | Executive Vice President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 362,318 | 362,318 | - | - | Performance-Based Restricted Stock Units | |
| Amneal Pharmaceuticals Inc... | Anastasios G. Konidaris | Executive Vice President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 181,159 | 181,159 | - | - | Restricted Stock Units | |
| Amneal Pharmaceuticals Inc... | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2022 | 36,197 | 108,591 | - | - | Restricted Stock Units | |
| Amneal Pharmaceuticals Inc... | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2022 | 36,197 | 123,916 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharmaceuticals Inc... | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2021 | 87,719 | 263,158 | - | - | Restricted Stock Units | |
| Amneal Pharmaceuticals Inc... | Anastasios G. Konidaris | Executive Vice President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2021 | 87,719 | 87,719 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharmaceuticals Inc... | Anastasios G. Konidaris | Executive Vice President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 289,576 | 289,576 | - | - | Performance-Based Restricted Stock Units | |
| Amneal Pharmaceuticals Inc... | Anastasios G. Konidaris | Executive Vice President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 144,788 | 144,788 | - | - | Restricted Stock Units |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges